Document is current
Any future updates will be listed below
-
Authors
Teh, Boon Lin https://orcid.org/0000-0001-5455-0233
Li, Yanda
Nanji, Keean
Phillips, Mark https://orcid.org/0000-0003-0923-261X
Chaudhary, Varun https://orcid.org/0000-0002-9988-4146
Steel, David H. https://orcid.org/0000-0001-8734-3089
,
Sinawat, Suthasinee
Kang, Se Woong
Bae, Kunho
Riazi-Esfahani, Hamid
Khalili Pour, Elias
Khodabande, Alireza
Qu, Jinfeng
Zhao, Mingwei
Yao, Yuou
Sadda, Srinivas
Modi, Aditya
Anantharaman, Giridhar
- License Information
-
More Information
Article History
Received: 12 August 2024
Revised: 21 January 2025
Accepted: 29 January 2025
First Online: 8 February 2025
Competing interests
: VC is a member of the Eye editorial board, advisory board member for Novartis, Bayer, and Roche, and has received financial support from Novartis, Bayer, and Allergan all unrelated to this project. DHS has received consulting fees from Alcon, Gyroscope Therapeutics (a Novartis company), Alimera, Complement therapeutics, BVI, and Roche, and research funding from Alcon, Gyroscope Therapeutics, Boehringer Ingelheim, DORC, Roche, and Bayer all unrelated to this project. The other authors declare that they have no conflict of interest.
